Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 41,200 shares, an increase of 396.4% from the December 15th total of 8,300 shares. Based on an average daily volume of 27,200 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.2% of the shares of the stock are sold short.
Dominari Stock Performance
Shares of NASDAQ:DOMH traded up $0.03 on Wednesday, reaching $1.06. The company’s stock had a trading volume of 18,813 shares, compared to its average volume of 69,090. The company has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $1.66. Dominari has a 52-week low of $0.83 and a 52-week high of $3.20. The company has a market cap of $6.68 million, a P/E ratio of -0.27 and a beta of 1.03.
Dominari (NASDAQ:DOMH – Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.45) earnings per share for the quarter. Dominari had a negative return on equity of 32.89% and a negative net margin of 180.22%. The company had revenue of $4.04 million for the quarter.
Dominari Company Profile
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Featured Articles
- Five stocks we like better than Dominari
- The Risks of Owning Bonds
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- How Do Stock Buybacks Affect Shareholders?
- What is a Low P/E Ratio and What Does it Tell Investors?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.